Neuropeptide Y receptor

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
neuropeptide Y receptor Y1
Identifiers
SymbolNPY1R
Alt. symbolsNPYR
Entrez4886
HUGO7956
OMIM162641
RefSeqNM_000909
UniProtP25929
Other data
LocusChr. 4 q31.3-q32
neuropeptide Y receptor Y2
Identifiers
SymbolNPY2R
Entrez4887
HUGO7957
OMIM162642
RefSeqNM_000910
UniProtP49146
Other data
LocusChr. 4 q31
pancreatic polypeptide receptor 1
Identifiers
SymbolPPYR1
Alt. symbolsNPY4R, Y4, PP1
Entrez5540
HUGO9329
OMIM601790
RefSeqNM_005972
UniProtP50391
Other data
LocusChr. 10 q11.2
neuropeptide Y receptor Y5
Identifiers
SymbolNPY5R
Entrez4889
HUGO7958
OMIM602001
RefSeqNM_006174
UniProtQ15761
Other data
LocusChr. 4 q31-q32

Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]

Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.

Only the crystal structure of Y1 in complex with two antagonist is available.[8]

Types[edit]

There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[9] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[10][11][12]

Antagonists[edit]

References[edit]

  1. ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.
  2. ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides. 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
  3. ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids. 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
  4. ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry. 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.
  5. ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery. 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.
  6. ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry. 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.
  7. ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
  8. ^ Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B (April 2018). "1 receptor". Nature. 556 (7702): 520–524. doi:10.1038/s41586-018-0046-x. PMC 5920736. PMID 29670288.
  9. ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides. 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
  10. ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews. 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
  11. ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry. 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.
  12. ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry. 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.

External links[edit]